Cancer

News

AZ/Merck & Co's Lynparza scores huge ovarian cancer win

AstraZeneca and Merck & Co’s Lynparza (olaparib) has massively reduced the risk of BRCA-mutated ovarian cancer progressing in patients who have just been treated with chemo, in trial re

News

Roche's Tecentriq posts trial wins in two key indications

Roche has scored two big wins with its Tecentriq cancer immunotherapy at ESMO in tough to treat triple negative breast cancer, and untreated lung cancer, as the company plays catch-up with

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Debates & Insight

Can simulated datasets unlock the potential of patient data?

Overview

News

First line kidney cancer could get crowded as Merck KGaA/Pfi...

Competition in first line kidney cancer is heating up after Germany’s Merck KGaA and Pfizer briefed the ESMO conference with detailed results of their combination of the Bavencio immunother

News

BMS' Opdivo+Yervoy could become first choice for certain col...

Bristol-Myers Squibb’s Opdivo and Yervoy combination could become first line treatment for a small group of metastatic colorectal cancer patients with aggressive tumours, on the basis of da

News

Novartis wants to blaze a trail in breast cancer with PI3K d...

Novartis is preparing to file its PI3K drug combination for a certain group of breast cancer patients, after late stage trial results showed its alpelisib combination stopped the disease pr

AZ/Merck & Co's Lynparza scores huge ovarian cancer win

Roche's Tecentriq posts trial wins in two key indications

Can simulated datasets unlock the potential of patient data?

First line kidney cancer could get crowded as Merck KGaA/Pfi...

BMS' Opdivo+Yervoy could become first choice for certain col...

Novartis wants to blaze a trail in breast cancer with PI3K d...

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

Cancer

Editor's Picks